Sun Pharma launches generic Glumetza

Sun Pharma enters in a competitive Metformin market in which Lupin enjoyed a 180-day exclusivity in 2016, while Teva has also been present. The drug size has shrunk by 63% since Sun Pharma received the approval in 2016.

Jul 25, 2018 02:07 IST India Infoline News Service

Sun Pharma has launched the generic versions Metformin HCL - ER tablets, 500 mg and 1,000 mg in the US market. These generic Metformin HCl extended release tablets are the therapeutic equivalents of Santarus Inc.’s Glumetza HCl ER tablets.

Sun Pharma had received approval for this drug in August 2016 when the addressable size of the market was $1.2bn. 

Lupin had a FTF of this drug and in February 2016, it launched generic of version of this drug. Teva also launched its own copycat of this drug in May 2017.

As per IQVIA, the current addressable market size for this drug is ~$443mn for the 12 months ending April 2018.
Sun Pharma, after it received EIR for Halol Facility in June 2018, has received its first ANDA approval from this facility recently. 

Sun Pharmaceuticals Industries Ltd is currently trading at Rs557.70 down by Rs4.8 or 0.85% from its previous closing of Rs562.50 on the BSE.

Related Story